Key Insights

Highlights

Treatment Research

5 treatments under study, led by Plerixafor

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Enrolling By Invitation2
Unknown1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06851767Phase 1/2Enrolling By Invitation

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

NCT01346150Unknown

Patients Treated for SCID (1968-Present)

NCT01186913Enrolling By Invitation

Natural History Study of SCID Disorders

Showing all 3 trials

Research Network

Common Treatments

  • Plerixafor1
  • Baseedited Hematopoietic Stem And Progenitor Cells1
  • Busulfan1
  • Palifermin1
  • Filgrastim1

Active Sponsors

  • National Institute of Allergy and Infectious Diseases (NIAID)3
  • National Center for Advancing Translational Sciences (NCATS)2
  • Primary Immune Deficiency Treatment Consortium (PIDTC)2
  • Office of Rare Diseases (ORD)1

Top Investigators

Related Conditions

  • Leaky Scid2
  • Omenn Syndrome2
  • Reticular Dysgenesis2
  • Adascid1
  • Scid1

Activity Timeline